FILTER

FILTERED INTERVIEW RESULTS

Sven Lunsche

VP CORPORATE AFFAIRS, GOLD FIELDS
Gold Fields discusses the future strategy for its South Deep asset.

Alok Shrivastava

MANAGING DIRECTOR AND CEO, ICVL
The Indian consortium International Coal Ventures Limited (ICVL) restarted mining coking coal at its assets in the western Mozambican province of Tete.

Eric Bruggeman

CEO, SA CAPITAL EQUIPMENT EXPORT COUNCIL (SACEEC)
The SACEEC assists its members to export their products in an effort to increase South Africa’s manufacturing capabilities.

Nicolas Konialidis & Craig Mynhardt

CEO & GM FOR AFRICA, IMPALA TERMINALS
Impala Terminals is expanding its services in sub Saharan Africa in tandem with the development of the mining industry and with the continents infrastructure developments.

Geert Klok

GENERAL MANAGER, GK ANCUABE GRAPHITE MINE, S.A.
GK Ancuabe graphite mine has expanded its capacity, offering an alternative to graphite from China and demonstrating that successful mining can be achieved in Mozambique.

Gareth Clifton

GENERAL MANAGER MOZAMBIQUE, KENMARE RESOURCES
Kenmare discusses its operations in Mozambique and the challenges currently facing the country.

Errol Smart

MD AND CEO, ORION MINERALS
Orion Minerals will be South Africa’s next copper and zinc producer with the Prieska project being a copper-predominant project. Full development is scheduled to begin in early 2020.

Roger Dixon

CORPORATE CONSULTANT, SRK CONSULTING
SRK’s team in South Africa sees increased opportunity in environmental and social governance issues.

Olivier Duterme

REGIONAL DIRECTOR, BANQUE COMMERCIALE DU CONGO (BCDC)
BCDC has existed as a leading domestic bank for 110 years in the Democratic Republic of Congo.

Paulo Reis

MANAGING PARTNER, EY MOZAMBIQUE
EY Mozambique sees opportunity to capitalize on the extractive industries to benefit the country’s development of other sectors.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS